MAOA
ENSG00000189221
Target class
Enzyme
Chromosome
X
Approved drugs
12
Clinical candidates (approved and in development)
14
- Approved drugs
- 12
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 14
- Chemical probe available
- Yes
- Target name
- MAOA
- Gene name
- Monoamine oxidase A
- Gene symbol
- MAOA
- Protein name
- Amine oxidase [flavin-containing] A (EC 1.4.3.21) (EC 1.4.3.4) (Monoamine oxidase type A) (MAO-A)
- Gene biotype
- Protein coding
- Gene family
- Flavoproteins
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 133.87
- Tissue specificity (Gini)
- 0.448
- Tissue specificity (tau)
- 0.656
- KEGG gene identifiers
- hsa:4128
- Protein interaction confidence
- 0.89419
- Protein interaction partners
- 58
- R-HSA-141333
- R-HSA-181430
- R-HSA-379397
- R-HSA-379398
- R-HSA-379401
- R-HSA-380612
- R-HSA-5579012
- R-HSA-6785807
- End position
- 43746821
- Start position
- 43654907
- Chromosome
- X
- Strand
- Forward
- Mitochondrion outer membrane
- Single-pass type IV membrane protein
- Cytoplasmic side .
- Mitochondria
- Tissue specificity (tau)
- 0.655604
- Expression inequality (Gini)
- 0.447818
Expression in transcripts per million
- Adipose - Subcutaneous
- 133.87
- Small Intestine - Terminal Ileum
- 131.61
- Esophagus - Muscularis
- 125.75
- Bladder
- 118.36
- Artery - Tibial
- 116.52
Expression in transcripts per million
- Adipose - Subcutaneous133.87
- Small Intestine - Terminal Ileum131.61
- Esophagus - Muscularis125.75
- Bladder118.36
- Artery - Tibial116.52
- Thyroid114.97
- Colon - Transverse110.03
- Esophagus - Gastroesophageal Junction101.1
- Lung100.67
- Adipose - Visceral (Omentum)90.5
- Colon - Sigmoid86.17
- Breast - Mammary Tissue78.94
- Artery - Coronary77.98
- Fallopian Tube77.17
- Prostate65.25
- Artery - Aorta64.38
- Vagina63.14
- Ovary57.23
- Stomach55.81
- Esophagus - Mucosa55.72
- Cells - Cultured fibroblasts46.96
- Skin - Not Sun Exposed (Suprapubic)46.9
- Cervix - Ectocervix45.59
- Nerve - Tibial44.53
- Skin - Sun Exposed (Lower leg)42.13
And 29 more, listed on the interactive page.
- GO:0006576
- GO:0042420
- GO:0005739
- GO:0005741
- GO:0005515
- GO:0008131
- GO:0097621
weakness
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: weakness
- cardiovascular system
- central nervous system
Evidence sourcedrug-drug interactions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: drug-drug interactions
- Pharmaco-kinetics
- central nervous system
PubMed 28216264tremors
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: tremors
- Pharmaco-kinetics
- central nervous system
PubMed 28216264dizziness
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: dizziness
- cardiovascular system
- central nervous system
Evidence sourcenausea
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: nausea
- Pharmaco-kinetics
- central nervous system
PubMed 28216264hypomania
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: hypomania
- cardiovascular system
- central nervous system
Evidence sourceserotonin syndrome
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: serotonin syndrome
- cardiovascular system
- central nervous system
Evidence sourcesleep disturbances
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: sleep disturbances
- Pharmaco-kinetics
- central nervous system
PubMed 28216264dizziness
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dizziness
- Pharmaco-kinetics
- central nervous system
PubMed 28216264decreased aggression
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased aggression
- Pharmaco-kinetics
- central nervous system
PubMed 28216264blurred vision
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: blurred vision
- cardiovascular system
- central nervous system
Evidence sourceweakness
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: weakness
- Pharmaco-kinetics
- central nervous system
PubMed 28216264decreased anxiety
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased anxiety
- Pharmaco-kinetics
- central nervous system
PubMed 28216264fatigue
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: fatigue
- Pharmaco-kinetics
- central nervous system
PubMed 28216264hypertensive when combined with pressor amines such as tyramine present in cheese: inhibitors may induce severe hypertensive crisis (known as "cheese reaction")
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: hypertensive when combined with pressor amines such as tyramine present in cheese: inhibitors may induce severe hypertensive crisis (known as "cheese reaction")
- cardiovascular system
- central nervous system
Evidence source
dizziness
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: dizziness
- cardiovascular system
- central nervous system
PubMed 23197038increased blood pressure when combined with amines such as tyramine
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased blood pressure when combined with amines such as tyramine
- cardiovascular system
- central nervous system
PubMed 23197038drug-drug interaction potential
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: drug-drug interaction potential
- cardiovascular system
- central nervous system
PubMed 23197038nausea
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: nausea
- cardiovascular system
- central nervous system
PubMed 23197038sleep disturbances
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: sleep disturbances
- cardiovascular system
- central nervous system
PubMed 23197038
Related records
Trials (210)
- 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province
- A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study
- A P3 Comparator Trial in Community Acquired Bacterial Pneumonia
- A PAN-USR TB Multi-Center Trial
- A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
- A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
- A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections
- A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK
- A Pilot Study Assessing EmSam in Bipolar Depression
- A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain
- A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.
- A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure
- A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
- A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis
- A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
- A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects
- A Study To Assess The Effect Of Linezolid On QTc Interval
- A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects
- AbioKin - Antibiotic Kinetics
Drugs (24)
- Befloxatone
- Bifemelane
- Clorgiline
- Indantadol Monoamine oxidase A inhibitor
- Iproniazid Monoamine oxidase inhibitor
- Isocarboxazid Monoamine oxidase inhibitor
- Linezolid
- Mebanazine Monoamine oxidase inhibitor
- Minaprine Monoamine oxidase A inhibitor
- Minaprine hydrochloride Monoamine oxidase A inhibitor
- Moclobemide Monoamine oxidase A inhibitor
- Nialamide Monoamine oxidase inhibitor
- Pargyline Monoamine oxidase inhibitor
- Pargyline hydrochloride Monoamine oxidase inhibitor
- Phenelzine Monoamine oxidase inhibitor
- Phenelzine sulfate Monoamine oxidase inhibitor
- Pheniprazine
- Phenoxypropazine Monoamine oxidase inhibitor
- Pirlindole
- Proxibarbal Monoamine oxidase A activator